Tenderwize
Back to tender search

Open-House Rituximab discount agreement for Lower Saxony, Bremen and Saxony-Anhalt

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Apr 21, 2027 · 248 days left·Open·Supplies·Framework
Original notice title

Germany – Pharmaceutical products – Open-House Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V Rituximab, ATC L01FA01 - Vertragsregionen Niedersachsen, Bremen und Sachsen-Anhalt

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

62 / 100

Complexity

58 / 100

Risk factors

The signed contract must be submitted in handwritten paper form, while only the separate file is sent electronically. M...

Only pharmaceutical undertakings, or a consortium of such undertakings, may contract, and the seat requirement is limit...

No procurement documents available

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply-related Open-House discount agreements for Rituximab (ATC L01FA01).
  • Applies to in-pharmacy prepared parenteral preparations from finished medicinal products in oncology for immediate physician use.
Show full summary

Open-House supply arrangement for Rituximab (CPV 33600000) covering the regions of Lower Saxony/Bremen and Saxony-Anhalt. The notice states that identical, non-exclusive discount agreements will be offered to all interested pharmaceutical companies meeting the stated eligibility conditions. No contract value is provided. Submission is by handwritten signed paper originals plus one electronic file by email; electronic submission of the signed contract itself is not allowed. The notice is in German and the analysis is based on the notice/XML only, with no procurement document text analyzed.

Risks

The signed contract must be submitted in handwritten paper form, while only the separate file is sent electronically. M...

Only pharmaceutical undertakings, or a consortium of such undertakings, may contract, and the seat requirement is limit...

No procurement documents available

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of § 4 Abs. 18 AMG, or a contracting group of pharmaceutical undertakings, for the offered medicinal products.
  • The company must have its seat in Germany, another EU Member State, or another EEA State, as stated in the notice.
  • Local representatives may participate only if they themselves qualify as pharmaceutical undertakings for the offered medicinal products.

Award Criteria

Lot 1

Price criterion stated at lot level; no weight provided.

Buyer

Location

Hannover, DEU

Identifier

AOK- Niedersachsen. Die Gesundheitskasse

Activity

Health

Lots (1)

LOT-0000

Open-House Rituximab discount agreement for Lower Saxony, Bremen and Saxony-Anhalt

Open-House non-exclusive pharmaceutical discount agreement for Rituximab, ATC L01FA01, for parenteral preparations used in oncology for immediate physician use. The notice says the arrangement is offered for two regional lots: Lot 1 (Lower Saxony/Bremen) and Lot 2 (Saxony-Anhalt), but the structured lot data does not separate them further. Lot-specific value is not provided.

SuppliesFrameworkEU fundedElectronic submission

Location

DE929, Germany

Duration

Jun 2025 - Jun 2027

Category

Pharmaceutical products

Award Criteria

Price

Deadline

Deadline Apr 21, 2027

Procurement Details

Publication date
27 Apr 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
270364-2025

Similar tenders